Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1. The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property[…]
New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2023 Tags: AIDSHIV Dec 21, 2015
New Tenofovir Pro-Drug Offers Less Toxicity
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: HIVHIV infectionHIV virus Mar 25, 2013
On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]
Atazanavir Sulfate Gets a Nod at the 6th International AIDS Society Conference
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, Patent Expiration 2017 Tags: antiretroviralHIVNorvirRitonavir Jan 20, 2013
Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]
Fungal Infections Face a Force to be Reckoned With-Amphotericin B
Anti-Fungal, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2016 Tags: Amphotericin BHIV Aug 14, 2012
Amphotericin B is also known as the brand name Ambisone. With Astellas Pharma’s patent for Ambisome due to expire on February 23, 2016, this injectable medication for deadly fungal infections is geared up for attention in the pharmaceutical community. More than 6 billion dollars is spent worldwide on anti-fungal medications, and the total costs of[…]
Tesamorelin and Breaking News from the United Nations AIDS Program
Anti-Retroviral / Anti-HIV, Antiviral Tags: antiretroviral therapyHIV Jul 19, 2012
The United Nations AIDS program announced on Wednesday, July 18th, 2012 that fewer people infected with HIV globally were dying, particularly in sub-Saharan Africa. The reason for this encouraging news is the greater accessibility for patients with AIDS worldwide to crucial antiretroviral drugs. The U.N. is actively working alongside pharmaceutical companies, in an effort to[…]
Life Extending Enfuvirtide Looks to Become a Successful Generic
Anti-Retroviral / Anti-HIV, Patent Expiration 2013, Patent Expiration 2015 Tags: AIDSHIVHIV infectionRitonavir Jun 27, 2012
In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]
Atazanavir Sulfate Essential Treatment for HIV Infected Patients
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: antiretroviralHIVRitonavir Feb 27, 2012
Atazanavir Sulfate, CAS# 229975-97-7, is essential in the management of HIV in affected patients. As an inhibitor of the HIV-1 protease, it is often used in combination with other antiretroviral medications to treat HIV-1 infected patients. LGM Pharma is a provider of the API for research and development. With a trade name Reyataz (Bristol-Myers Squibb),[…]
Monotherapy with Darunavir is Where the "MONET" is
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AIDSDarunavir EthanolateHIVHIV virusRitonavir Sep 02, 2011
AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]
Plerixafor – Primary Usage, Stem Cells, and Availability for R&D Purposes
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AIDSHIV Jan 19, 2011
Plerixafor is a new compound that can be used as an effective drug to cure cancer patients. This drug is an immunostimulant and is used to increase hematopoietic stem cells in patients suffering from cancer. The stem cells are then transplanted into the patients. Initially, this drug was developed to help HIV patients because it[…]
Darunavir Ethanolate – Anti-Retroviral / Anti-HIV Therapeutic
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: Darunavir EthanolateHIVNorvir Jul 21, 2010
Darunavir Ethanolate CAS# 635728-49-3 is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs. Darunavir is always[…]
